Source: Eur Respir J 2012; 39: 9-28
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
Berghmans T., Pasleau F., Paesmans M., Bonduelle Y., Cadranel J., Cs Toth I., Garcia C., Giner V., Holbrechts S., Lafitte J.J., Lecomte J., Louviaux I., Markiewicz E., Meert A.P., Richez M., Roelandts M., Scherpereel A., Tulippe Ch., Van Houtte P., Van Schil P., Wachters C., Westeel V., Sculier J.P.. Surrogate markers predicting overall survival for lung cancer: ELCWP recommendations. Eur Respir J 2012; 39: 9-28

Member's Comments

No comment yet.

Related content which might interest you: Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis Source: Eur Respir J 2001; 18: 705-719 Year: 2001 Lung cancer survival in the UK: are the results from the national lung cancer audit (LUCADA) dependent on completeness of case reporting? Source: Annual Congress 2009 - Epidemiology and management of lung cancer Year: 2009 Validation and comparison of several published prognostic systems for patients with small cell lung cancer Source: Eur Respir J 2011; 38: 657-663 Year: 2011 COX-2 as prognostic factor in lung cancer: systematic review of the literature with meta-analysis Source: Annual Congress 2005 - Prognostic factors in lung cancer Year: 2005 Enrolment in clinical trials enhances the survival benefit provided to lung cancer patients Source: International Congress 2016 – Prognostic variables in lung cancer II Year: 2016 Development and validation of a prognostic index for survival in patients with non-small-cell lung cancer Source: International Congress 2016 – Prognostic variables in lung cancer II Year: 2016 Clinical factors of long-term survival in patients with advanced lung cancer Source: International Congress 2017 – Lung cancer: clinically relevant aspects of epidemiology, co-morbidities, metastasised disease and follow-up Year: 2017 Commentary: The ERS/ESTS clinical guidelines for evaluating fitness for radical treatment for lung cancer Source: Breathe 2008; 6: 141-145 Year: 2009 The Liverpool Lung Project: a molecular epidemiological study of early lung cancer detection Source: Eur Respir J 2002; 20: 464-479 Year: 2002 Treatment and survival in patients with pulmonary carcinoid tumours; an updated analysis from the UK national lung cancer audit Source: International Congress 2015 – Thoracic oncology around the world: rare cases and local features Year: 2015 The role of angiogenesis, assessed by microvessel count (MVC), on the survival of patients with lung cancer: a systematic review of the literature with meta-analysis Source: Eur Respir J 2002; 20: Suppl. 38, 3s Year: 2002 The impact of lung cancer resection surgery on fibrinogen and C-reactive protein and their relationship with patients outcomes: A prospective follow up study Source: International Congress 2016 – Special issues in thoracic surgery Year: 2016 Lung cancer screening: the critical review Source: International Congress 2015 – Lung cancer screening: how to implement a comprehensive preventive approach Year: 2015 Chemotherapy improves low performance status lung cancer patients Source: Eur Respir J 2007; 30: 1186-1192 Year: 2007 Brain metastasis as initial presentation of lung cancer - Impact of prognostic factors on patient survival Source: International Congress 2017 – Lung cancer - clinical research: scientific pearls from the bedside Year: 2017 Role of biomarkers for early detection of lung cancer and chemoprevention Source: Eur Respir J 2002; 19: 1151-1158 Year: 2002 A new TNM classification is better than ISS at predicting survival in stage III unresectable non-small cell lung cancer (NSCLC). A study by the European lung cancer working party (ELCWP) Source: Eur Respir J 2003; 22: Suppl. 45, 163s Year: 2003 A prospective study of survival after surgery for early stage non-small cell lung cancer in patients with COPD Source: International Congress 2015 – Risk assessment and prevention of complications in thoracic surgery Year: 2015 Biomarkers for non-small cell lung cancer (NSCLC) treatment: examples and unmet needs, a clinical perspective Source: International Congress 2014 – From bench to bedside: biomarkers and biobanking for lung cancer in 2014 Year: 2014 Customising chemotherapy in advanced nonsmall cell lung cancer: daily practice and perspectives Source: Eur Respir Rev 2011; 20: 45-52 Year: 2011